Möchten Sie immer auf dem neuesten Stand bleiben?

Stellantis Resets its Business to Meet Customer Preferences and to Support Profitable Growth H2 2025 charges of approximately €22 billion primarily reflect a strategic shift to put freedom of choice...

Premio di risultato per l’anno 2025 ai dipendenti di CNH in Italia Torino, 3 febbraio, 2026 CNH, nel corso di un incontro tenutosi oggi con le Organizzazioni Sindacali, ha presentato i valori del...

Maranello (Italy), February 2 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on...

mRNA-3927 si inserisce strategicamente nel portafoglio delle malattie rare metaboliche di Recordati La collaborazione unisce l’expertise di Moderna nella tecnologia mRNA per i disturbi metabolicirari...

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

Stellantis to Present Strategic Plan at May 21 Investor Day  AMSTERDAM, January 29, 2026 – Stellantis N.V. announced today that the Company will present its strategic plan at its Investor Day 2026,...

Maranello (Italy), January 26 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on...

Iveco Group to present 2025 Fourth Quarter and Full Year Results on 12th February 2026 Transactions progressing as planned with the expected dividend for the Defence separation remaining at €5.5-6.0...

CNH to announce 2025 Q4 & Full Year results on February 17 Basildon, January 20, 2026 CNH (NYSE: CNH) will release its financial results for the Fourth Quarter & Full Year of 2025 on...

Maranello (Italy), January 19 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on...